GlobeNewswire 8/19/2024 Tiziana Life Sciences Appoints New Chief Executive Officer
GlobeNewswire 8/19/2024 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire 8/19/2024 CN Issues Lockout Notice to Teamsters
GlobeNewswire 8/15/2024 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire 8/14/2024 Progressive Reports July 2024 Results
GlobeNewswire 8/14/2024 Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene ...
GlobeNewswire 8/14/2024 Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
GlobeNewswire 8/13/2024 Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire 8/12/2024 Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Newsfile Corp 8/12/2024 The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
TeleTrader 8/11/2024 Bank of Russia says rates could reach 20%
GlobeNewswire 8/8/2024 Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15,...
GlobeNewswire 8/8/2024 Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
GlobeNewswire 8/7/2024 Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Sus...
GlobeNewswire 8/7/2024 AGS Unveils its Latest Table Innovation Bonus Spin Xtreme for Poker Rooms and an Exciting New Lineup...
GlobeNewswire 8/7/2024 Team, Inc. Announces Timing of Second Quarter Earnings Release and Conference Call
TeleTrader 8/7/2024 Cori Bush loses Missouri Democratic primary
GlobeNewswire 8/6/2024 TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy)...
GlobeNewswire 8/6/2024 Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, fo...
TeleTrader 8/6/2024 Aramco's Q2 net income down 3.2% to $29.1 billion
GlobeNewswire 8/5/2024 Progressive Announces Quarterly Common Share Dividend
GlobeNewswire 8/5/2024 NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted...
GlobeNewswire 8/5/2024 Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
GlobeNewswire 7/30/2024 Progressive Announces Investor Relations Event
GlobeNewswire 7/30/2024 Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dr...